Impetigo Drug Market Will Generate Record Revenue by 2029

Impetigo drug market is anticipated to grow at a significant CAGR during the forecast period. Impetigo is a bacterial infection of the skin. It is most common in young children. It is caused by one or both of the bacteria including group A Streptococcus and Staphylococcus aureus. The major factor driving the demand for impetigo drug is the increasing prevalence of impetigo across the globe.

According to the National Center for Biotechnology Information (NCBI), in the pediatric population, impetigo accounts for approximately 10% of skin complaints. Additionally, the incidence is the same in males and females considering all ages. In adults, men are more commonly affected. Furthermore, it is most prevalent in children aged 2-5 years old, however, it can occur at any age. Children younger than two years account for 90% of cases of bullous impetigo. Moreover, as per the World Health Organization (WHO), it is estimated that 111 million children have streptococcal impetigo at any one time globally. Hence, the increasing prevalence of impetigo is driving the demand for impetigo drugs for treatment, which in turn, is driving the growth of the market.

Some major players in the market include GlaxoSmithKline plc, and Lytix Biopharma AS, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Foamix Pharmaceuticals Ltd. announced that they have signed a definitive merger agreement with Menlo Therapeutics Inc. The agreement was aimed to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space.

To Request a Sample of our Report on Impetigo Drug Market: https://www.omrglobal.com/request-sample/impetigo-drug-market

Market Coverage

• The market number available for - 2022-2030

• Base year- 2022

• Forecast period- 2023-2030

Segment Covered-

• By Type

• By Application

Regions Covered-

• North America

• Europe

• Asia-Pacific

• Rest of the World

Competitive Landscape- GlaxoSmithKline plc, and Lytix Biopharma AS, among others.

Impetigo Drug Market Report by Segment

By Type

• FMX-102

• LTX-109

• Mupirocin

• Ozenoxacin

• Others

By Application

• Clinic

• Hospital

• Others

A full Report of Impetigo Drug Market is Available @ https://www.omrglobal.com/industry-reports/impetigo-drug-market

Impetigo Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.